Potential oncogenic mutations found included PIK3CA, KRAS, PIK3R1, and FGFR2 in benign epithelial endometrium from women with uterine fibroids, and ARID1A mutations in endometrial stroma from women with endometriosis [131]. This evidence concerns the gene KRAS and uterine corpus leiomyoma.